By: Kwame Ulmer
There is a broad spectrum of advice MedTech companies receive regarding when, how, and on what topics to engage the United States Food & Drug Administration (FDA). Here is part 1 of the top 10 reasons it makes sense. I also share my thoughts on a common myth and reality when speaking to the FDA.
コメント